Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients |
| |
Authors: | Soriano Vincent Pérez-Olmeda Mayte Ríos Pilar Núñez Marina García-Samaniego Javier González-Lahoz Juan |
| |
Institution: | Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain. vsoriano@dragonet.es |
| |
Abstract: | The response to standard or pegylated interferon (IFN) plus ribavirin (RBV) seems to be lower in hepatitis C virus (HCV)/HIV-coinfected subjects than in HCV-monoinfected patients. Thus, the principles guiding anti-HCV therapy in HIV-negative patients may not apply in the setting of HIV infection. We examined the rate of HCV relapse in 58 HCV/HIV-coinfected subjects who showed undetectable HCV-RNA (<600 IU/ml) at the end of anti-HCV combination therapy. Overall, 19 (32.8%) patients relapsed after discontinuing treatment, a rate significantly higher than that seen in HIV negatives, which is in the range of 15-20%. There were no significant differences between HCV genotypes (33.3% for HCV genotypes 2-3 versus 31.8% for HCV genotypes 1-4) and/or the use of either standard or pegylated IFN (37% versus 29%, respectively). Thus, extended periods of anti-HCV therapy might reduce HCV relapses in HIV-coinfected patients initially responding to therapy. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|